Company Description
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields,...
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Valuation
P/E Current
42.17
P/E Ratio (without extraordinary items)
75.39
Price to Sales Ratio
12.69
Price to Book Ratio
5.56
Price to Cash Flow Ratio
102.95
Enterprise Value to EBITDA
64.56
Enterprise Value to Sales
7.38
Efficiency
Total Asset Turnover
0.40
Liquidity
Current Ratio
2.48
Quick Ratio
2.09
Cash Ratio
1.23
Profitability
Gross Margin
69.69
Operating Margin
6.32
Pretax Margin
19.53
Net Margin
16.84
Return on Assets
6.68
Return on Equity
9.87
Return on Total Capital
2.88
Capital Structure
Total Debt to Total Assets
16.69
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Francis A. deSouza | 48 | 2013 | President |
Mr. Kevin Pegels | - | 2021 | Chief-Global Operations |
Dr. Joydeep Goswami | 48 | 2019 | SVP-Corporate Development & Strategic Planning |
Dr. Alex Aravanis | - | 2020 | Chief Technology Officer & Senior Vice President |
Ms. Carissa Rollins | - | 2022 | Chief Information Officer |
Insider Actions
01/09/2023 |
Aimee Hoyt SVP, Chief People Officer |
871 | Disposition at $205.57 per share. | 179,051 |
01/06/2023 |
Susan H. Tousi SVP, Chief Commercial Officer |
500 | Disposition at $204.58 per share. | 102,290 |
12/06/2022 |
Susan H. Tousi SVP, Chief Commercial Officer |
500 | Disposition at $212.63 per share. | 106,315 |
11/08/2022 |
Alex Aravanis SVP, Chief Technology Officer |
361 | Disposition at $218 per share. | 78,698 |
11/07/2022 |
Susan H. Tousi SVP, Chief Commercial Officer |
500 | Disposition at $223.65 per share. | 111,825 |
11/07/2022 |
Aimee Hoyt SVP, Chief People Officer |
1,045 | Disposition at $223.65 per share. | 233,714 |
11/07/2022 |
Aimee Hoyt SVP, Chief People Officer |
1,294 | Disposition at $223.65 per share. | 289,403 |
11/05/2022 |
Francis A. deSouza President and CEO; Director |
2,591 | Derivative/Non-derivative trans. at $217.19 per share. | 562,739 |
11/05/2022 |
Susan H. Tousi SVP, Chief Commercial Officer |
721 | Derivative/Non-derivative trans. at $217.19 per share. | 156,593 |
11/05/2022 |
Joydeep Goswami SVP Corp Business Development |
638 | Derivative/Non-derivative trans. at $217.19 per share. | 138,567 |
11/05/2022 |
Charles E. Dadswell SVP & General Counsel |
853 | Derivative/Non-derivative trans. at $217.19 per share. | 185,263 |
11/05/2022 |
Kevin Pegels Chief of Global Operations |
472 | Derivative/Non-derivative trans. at $217.19 per share. | 102,513 |
11/05/2022 |
Scott Ericksen VP, Chief Accounting Officer |
213 | Derivative/Non-derivative trans. at $217.19 per share. | 46,261 |
11/05/2022 |
Phillip G. Febbo SVP Chief Medical Officer |
821 | Derivative/Non-derivative trans. at $217.19 per share. | 178,312 |
11/05/2022 |
Kathryne Reeves SVP, Chief Marketing Officer |
212 | Derivative/Non-derivative trans. at $217.19 per share. | 46,044 |
11/05/2022 |
Aimee Hoyt SVP, Chief People Officer |
640 | Derivative/Non-derivative trans. at $217.19 per share. | 139,001 |
11/05/2022 |
Alex Aravanis SVP, Chief Technology Officer |
191 | Derivative/Non-derivative trans. at $217.19 per share. | 41,483 |
10/06/2022 |
Susan H. Tousi SVP, Chief Commercial Officer |
500 | Disposition at $216.59 per share. | 108,295 |
10/05/2022 |
Joydeep Goswami SVP Corp Business Development |
165 | Derivative/Non-derivative trans. at $218.52 per share. | 36,055 |
10/05/2022 |
Kathryne Reeves SVP, Chief Marketing Officer |
73 | Derivative/Non-derivative trans. at $218.52 per share. | 15,951 |
07/07/2022 |
Alex Aravanis SVP, Chief Technology Officer |
539 | Disposition at $200 per share. | 107,800 |
07/05/2022 |
Alex Aravanis SVP, Chief Technology Officer |
285 | Derivative/Non-derivative trans. at $193.02 per share. | 55,010 |
MarketWatch News on ILMN
-
Illumina Inc. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Illumina Inc. stock rises Thursday, still underperforms market
- MarketWatch Automation
-
Illumina Inc. stock underperforms Wednesday when compared to competitors
- MarketWatch Automation
-
Illumina Inc. stock falls Tuesday, underperforms market
- MarketWatch Automation
-
Illumina Inc. stock rises Monday, outperforms market
- MarketWatch Automation
-
Illumina Inc. stock falls Thursday, underperforms market
- MarketWatch Automation
-
Illumina Inc. stock falls Wednesday, still outperforms market
- MarketWatch Automation
-
Illumina Inc. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Why Chip Maker Nvidia Was at a Healthcare Conference
- Barron's Online
-
Illumina Inc. stock rises Friday, outperforms market
- MarketWatch Automation
-
Illumina Inc. stock underperforms Thursday when compared to competitors
- MarketWatch Automation
-
Illumina Inc. stock outperforms market on strong trading day
- MarketWatch Automation
-
Illumina Inc. stock underperforms Tuesday when compared to competitors
- MarketWatch Automation
-
Why Illumina Has Grown Cautious and What It Means for the Stock
- Barron's Online
-
Illumina Inc. stock rises Monday, outperforms market
- MarketWatch Automation
-
Why a Long-Term Investor Is Sticking With Tesla and Cloud Shares
- Barron's Online
-
Illumina Inc. stock rises Friday, still underperforms market
- MarketWatch Automation
-
Illumina Inc. stock underperforms Thursday when compared to competitors
- MarketWatch Automation
- Loading more headlines...
Other News on ILMN
-
Baillie Gifford Slashes Meta, Boosts Nvidia
- GuruFocus.com
-
Top 5 4th Quarter Trades of Amazon com Inc
- GuruFocus.com
-
STONNINGTON GROUP, LLC Buys 2, Sells 3 in 4th Quarter
- GuruFocus.com
-
Aurora Investment Managers, LLC. Buys 3, Sells 2 in 4th Quarter
- GuruFocus.com
-
Illumina: A Growth Stock in Waiting
- GuruFocus.com
-
Guardant Health Drops 30% as Cancer Test Disappoints
- GuruFocus.com
-
Among the Best-Managed Companies of 2022, Some Warning Signs
- Chris Kornelis
-
Illumina to shed 5% of global headcount
- Seeking Alpha
-
Alyeska Investment Group, L.P. Buys 4, Sells 1 in 3rd Quarter
- GuruFocus.com
-
Twist Bioscience: Cash Burn Continues To Be The Issue
- Seeking Alpha
-
POLEN CAPITAL MANAGEMENT LLC Buys 2, Sells 3 in 3rd Quarter
- GuruFocus.com
-
Illumina, Inc. (ILMN) Q3 2022 Earnings Call Transcript
- Seeking Alpha
-
Illumina slips as GRAIL impairment prompts guidance cut
- Seeking Alpha
- Loading more headlines...